Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses

Area of Science:

• Virology
• Immunology
• Hepatology

Background:

• Hepatitis B and C viruses (HBV and HCV) cause significant global mortality, with aging populations exacerbating the public health challenge.
• While direct-acting antivirals have improved HCV treatment, chronic HBV therapy remains limited, rarely achieving viral clearance.
• Interferon, a key antiviral defense, has historically been used for both HBV and HCV, though newer targeted therapies are emerging.

Purpose of the Study:

• To review the current understanding of interferon's role in combating HBV and HCV.
• To explore the significance of type III interferon and IFNL4 in innate antiviral responses.
• To identify potential new therapeutic targets based on interferon signaling pathways.

Main Methods:

• Literature review of studies on HBV, HCV, interferon therapy, and interferon signaling pathways.
• Analysis of recent discoveries concerning type III interferon and IFNL4.
• Synthesis of information on the mechanisms of interferon-stimulated gene (ISG) activation.

Main Results:

• Interferon remains a partially effective treatment for both HBV and HCV, despite the development of targeted therapies.
• The discovery of type III interferon and IFNL4 provides novel insights into the innate immune response to viral infections.
• Understanding ISG activation mechanisms highlights potential new avenues for therapeutic intervention.

Conclusions:

• Despite advances in treatment, HBV and HCV continue to pose significant health threats.
• Type III interferon and IFNL4 represent promising areas for future research and therapeutic development against viral hepatitis.
• Targeting interferon signaling pathways could offer new strategies for managing chronic HBV and HCV infections.